INTRODUCTION
Major depressive disorder (MDD) affects 6.8% of the US population and is a source of significant economic burden, with direct costs of $98.9 billion per year. 1 Psychiatric medications alone cost $30.3 billion per year, and costs for antidepressants are increasing up to 10% annually. [2] [3] [4] Depression is projected to rival only HIV/AIDS and heart disease as a leading cause of burden of disease by 2030. 5 It is estimated that mental illnesses have a disability-adjusted life year burden of 11%, causing at least 15 million disability-adjusted life years annually. 6 The social stigma of mental illness can prevent many individuals from seeking treatment, adding to reduced work productivity and increased health care burden. Of those individuals who do seek treatment for MDD, only one half are expected to respond to their first antidepressant and only one third are expected to achieve remission. 7 This lack of efficacy of medication treatment leads patients on a journey of multiple failed medication trials, often enduring undesirable side effects; as a result, patients are considered treatment resistant. treatment than to refer to a psychiatrist. However, the recent utilization of combinatorial PGx testing has proven to be much more successful at identifying patients taking genetically incompatible medications who are less likely to respond compared with patients taking more genetically compatible medications. 20 Combinatorial PGx testing integrates a patient's unique genetic information across multiple genes with the pharmacology, pharmacokinetics, and pharmacodynamics of commonly prescribed medications to classify these medications based on a patient's level of gene-drug interactions. This combinatorial process allows HCPs to personalize medication selection for their patient.
To date, the only psychiatric combinatorial PGx testing platform with multiple prospective clinical trials supporting its clinical validity and utility over treatment as usual (TAU) is the combinatorial pharmacogenomic test GeneSight Psychotropic, powered by CPGx technology (Assurex Health, Mason, OH). [21] [22] [23] The proprietary GeneSight CPGx test algorithm stratifies 38 psychotropic medications into a use as directed (or "green") category, a use with caution (or "yellow") category, and a use with increased caution and with more frequent monitoring (or "red") category based on the severity of gene-drug interactions specific to each patient ( Figure 1 ). One study found that patients whose treatment was guided by using the combinatorial PGx test result exhibited 70% greater improvement in symptoms compared with patients whose treatment was not guided by these results. 22 A retrospective health care utilization study found that patients taking "red" category medications according to the combinatorial PGx test result had significantly more health care visits, more disability claims, and more medical absence days. 24 A second economic study, conducted by Medco (a pharmacy benefits manager), used data from 413,000 patients and prospectively showed that patients using the combinatorial (PGx) test saved $1036 per-member per-year (PMPY) on medication costs versus those patients who did not undergo combinatorial PGx testing. 25 Thus, average medication costs PMPY increased by $1725 from the pretest period to the end of study with TAU, which was significantly higher than the mean increase of $690 in the combinatorial PGx test group (P o 0.0001). The Medco study included patients treated in Clinical Therapeutics
